Tau Filament Structures Imaged With Cryo-electron Microscopy

The atomic structures of one of the two types of the abnormal filaments which lead to Alzheimer’s disease have, for the first time, been revealed by Medical Research Council researchers. Understanding the structures of these filaments will be key in developing drugs to prevent their formation.

The researchers believe the structures they have uncovered could also suggest how tau protein may form different filaments in other neurodegenerative diseases.

Alzheimer’s, the most common neurodegenerative disease, is characterised by the existence of two types of abnormal ‘amyloid‘ forms of protein which form lesions in the brain. Tau forms filaments inside nerve cells and amyloid-beta forms filaments outside cells.

Tau lesions appear to have a stronger correlation to the loss of cognitive ability in patients with the disease.

Tau Protein Lesions

Almost thirty years ago, scientists at the MRC Laboratory of Molecular Biology (LMB), including Michel Goedert, one of the senior authors on this paper, identified tau protein as an integral component of the lesions found in Alzheimer’s and a range of other neurodegenerative diseases. But, until now, scientists have been unable to identify the atomic structure of the filaments.

The researchers extracted tau filaments from the brain of a patient who had died with Alzheimer’s disease. The filaments were then imaged using cryo-electron microscopy (cryo-EM).

Senior author Sjors Scheres and colleagues developed new software in order to calculate the structure of the filaments in sufficient detail to deduce the arrangement of the atoms inside them. Scheres said:

“It’s very exciting that we were able to use this new technique to visualise filaments from a diseased brain as previous work depended on artificial samples assembled in the laboratory. Amyloid structures can form in many different ways, so it has been unclear how close these lab versions resembled those in human disease.

Knowing which parts of tau are important for filament formation is relevant for the development of drugs. For example, many pharmaceutical companies are currently using different parts of tau in tests to measure the effect of different drugs on filament formation; this new knowledge should significantly increase the accuracy of such tests.”

Fellow senior author Michel Goedert said:

“We have known for almost three decades that the abnormal assembly of tau protein into filaments is a defining characteristic of Alzheimer’s disease. In 1998, the dysfunction of tau protein was shown to be sufficient for neurodegeneration and dementia. In 2009, the prion-like properties of assembled tau were identified. These properties allow the abnormal form to convert previously normal forms.

Until now the high-resolution structures of tau or any other disease-causing filaments from human brain tissue have remained unknown. This new work will help to develop better compounds for diagnosing and treating Alzheimer’s and other diseases which involve defective tau.”

The work was supported by the UK Medical Research Council, the European Union, Joint Programme-Neurodegeneration Research, the US National Institutes of Health and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine.